Literature DB >> 2862927

Selective interaction of novel anxiolytics with 5-hydroxytryptamine1A receptors.

S J Peroutka.   

Abstract

Radioligand binding studies were used to analyze the interactions of two novel anxiolytics, buspirone and TVX Q 7821, with a series of 10 neuronal membrane receptor sites. Buspirone (IC50 = 24 nM) and TVX Q 7821 (IC50 = 9.5 nM) display the highest affinity for 5-hydroxytryptamine1A (5-HT1A) binding sites labeled by 3H-8-hydroxy-2-(di-n-pro-pylamino) tetralin (DPAT). By contrast, buspirone is 16-fold weaker at dopamine (D2) receptors (IC50 = 380 nM), whereas TVX Q 7821 is 6-fold less potent at alpha-adrenergic1 sites (IC50 = 58 nM). At the other receptors studied, buspirone and TVX Q 7821 had similar pharmacological profiles. Both agents display moderate affinity for histamine (H1), alpha-adrenergic2, and 5-HT2 binding sites. The drugs are essentially inactive at 5-HT1B, calcium channel antagonist, muscarinic cholinergic, and benzodiazepine receptors. These results suggest that the anxiolytic effects of buspirone and TVX Q 7821 may be mediated by central 5-HT1A receptors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2862927     DOI: 10.1016/0006-3223(85)90194-5

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  62 in total

1.  Effects of oral and intravenous administration of buspirone on food-cocaine choice in socially housed male cynomolgus monkeys.

Authors:  Paul W Czoty; Michael A Nader
Journal:  Neuropsychopharmacology       Date:  2015-03-13       Impact factor: 7.853

2.  Molecular structural basis of ligand selectivity for 5-HT2 versus 5-HT1C cortical receptors.

Authors:  P A Pierce; J Y Kim; S J Peroutka
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-07       Impact factor: 3.000

3.  Antidepressant-like activity of 5-HT1A agonists measured with the forced swim test.

Authors:  S Wieland; I Lucki
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

4.  Interactions of isamoltane (CGP 361A), an anxiolytic phenoxypropanolamine derivative, with 5-HT1 receptor subtypes in the rat brain.

Authors:  P C Waldmeier; M Williams; P A Baumann; S Bischoff; M A Sills; R F Neale
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-06       Impact factor: 3.000

5.  Serotonin involvement in the discriminative stimulus effects of kappa opioids in pigeons.

Authors:  M E Bronson; Y P Lin; K Burchett; M J Picker; L A Dykstra
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  The influence of ipsapirone, a 5-HT1A agonist, on sleep patterns of healthy subjects.

Authors:  H S Driver; M J Flanigan; A J Bentley; H G Luus; C M Shapiro; D Mitchell
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

7.  5-HT1A receptor agonists prevent in rats the yawning and penile erections induced by direct dopamine agonists.

Authors:  P Simon; B Guardiola; J Bizot-Espiard; P Schiavi; J Costentin
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

8.  Effect of the 5-HT1A partial agonist buspirone on regional cerebral blood flow in man.

Authors:  P M Grasby; K J Friston; C Bench; P J Cowen; C D Frith; P F Liddle; R S Frackowiak; R J Dolan
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

9.  The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism.

Authors:  Melanie A Paquette; Katherine Foley; Elizabeth G Brudney; Charles K Meshul; Steven W Johnson; S Paul Berger
Journal:  Psychopharmacology (Berl)       Date:  2009-03-13       Impact factor: 4.530

10.  Comparison of ketanserin, buspirone and propranolol on arousal, pupil size and autonomic function in healthy volunteers.

Authors:  Vassilis Koudas; Alexandra Nikolaou; Eugenia Hourdaki; Stella G Giakoumaki; Panos Roussos; Panos Bitsios
Journal:  Psychopharmacology (Berl)       Date:  2009-03-14       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.